Synergy studies were performed with metronidazole in combination with clindamycin, rifampin, nalidixic acid, ticarcillin, erythromycin, and spectinomycin against Bacteroides fragilis strains. An agar dilution technique was used with two inoculum sizes (106 to 107 or 103 to 104 colony-forming units per ml). None of the drugs showed synergy with metronidazole against greater than 50% of the strains, and the synergistic effect was generally less at the larger inoculum. Of the six drugs tested, nalidixic acid, clindamycin, and rifampin showed the most synergy with metronidazole. A partially synergistic or additive effect was the usual interaction occurring between metronidazole and each of the other drugs and no antagonism was seen.
In the treatment of serious infections, synergistic combinations of antibiotics are often used for a maximal therapeutic effect. A similar approach could apply in Bacteroides fragilis infections if synergy with a drug combination could be demonstrated against the majority of strains. Because of its consistent and rapid bactericidal activity (5, 7, 9) , metronidazole would likely be considered one of the drugs used in the combination, although only a few studies have examined its potential synergistic effects with other antimicrobial agents against B. fragilis (3, 8, 10) . In the study presented, six drugs which had demonstrated some synergistic activity with metronidazole were reexamined in combination with this drug against clinical isolates of B. fragilis. Two different inoculum sizes were used to determine whether this variable affected the demonstration of synergy.
MATERIALS AND METHODS Although the number of strains in which a strictly synergistic effect was present was generally small, a partially synergistic or additive effect was seen against the majority of strains with all the antimicrobial combinations, with the exception of spectinomycin (at the larger inoculum). No antagonism was seen with any combination.
DISCUSSION
The results of this in vitro study, using an agar dilution technique, demonstrate that synergy between metronidazole and any of the other six drugs tested occurs against a minority of strains of B. fragilis. Previously, Busch et al. had demonstrated synergy against 76% oftheir B. fragilis strains, using a combination of clindamycin and metronidazole (3) . This compares with a synergistic effect against only 24 and 14% of the strains used in our experiment at inocula of 103 to 104 and 106 to 107 CFU/ml, respectively. The reason for this discrepancy is not known, since the methodology was very similar in both studies. Moreover, in the same study, erythromycin was shown to be synergistic with metronidazole against 33% of the strains, but in our experiment, the combination was synergistic against only 13% at the lower inoculum and against none of the strains at the higher inoculum.
Rifampin or nalidixic acid in combination with metronidazole were shown to be synergistic against the one strain reported by Salem et al. (8) , but we were able to show synergy against only a relatively small number of strains in our study at the larger inoculum (less than 15%), although this more than doubled at the lower inoculum (23 to 42%).
Spectinomycin, which is bactericidal against B. fragilis (6), did not demonstrate significant synergy at either inoculum size when combined with metronidazole. Moreover, the median MICs of spectinomycin at the small and large inocula were 64 and 128 ,ug/ml, respectively, which were four-to eightfold greater than results obtained by Philips (6) . Methodological differences may have accounted for this since, for example, the pH of the medium is an important variable in susceptibility testing with spectinomycin (6) .
Ticarcillin, in our study, was synergistic with metronidazole in less than 5% of the strains, and this agrees with Busch et al. (3) , who found a low incidence of synergy with a similar drug, carbenicillin (14%). The mechanism of action of metronidazole has not been conclusively defined, although it appears that it is taken up by susceptible cells, transformed into an active intermediate which then interacts with the deoxyribonucleic acid (DNA) of the cell, causing cell death (2) . Its ultimate site of action, i.e., the DNA of the cell, corresponds to that of nalidixic acid, and it is interesting to note that this drug showed the most synergy with metronidazole. This relationship was previously noted by Salem et al. (8) .
Since metronidazole is extremely effective alone in vitro and bactericidal concentrations are easily attained in serum and other body tissues (2), the lack of synergy with any combination against the majority of strains of B. fragilis would militate against its being used in combination empirically with any of the other drugs tested in this study for a synergistic effect. Only on rare occasions would it be necessary to consider a combination, in view of potential side effects from additional antimicrobial agents, and under these circumstances appropriate synergy studies should be carried out before a combination is prescribed. Conversely, if metronidazole had to be combined with any of the other six drugs tested, there is no evidence from this study to suggest there would be any antimicrobial antagonism in treating B. fragilis infections. Moreover, a partially synergistic or additive effect would be expected against the majority of strains.
